Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Perrigo Company plc    PRGO   IE00BGH1M568

PERRIGO COMPANY PLC

(PRGO)
  Report
Delayed Quote. Delayed Nyse - 03/27 04:10:00 pm
46.1 USD   -0.95%
03/10PERRIGO COMPANY PLC : Report
CO
03/06PERRIGO COMPANY PLC : Report
CO
03/05PERRIGO COMPANY PLC : Report
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Perrigo Company plc
Perrigo Company plc develops, produces, and sells therapy and care products. Sales break down by product family as follows:

- consumable care products (80%). The group also offers medical diagnostic products. Net sales break down by geographical area between the United States/Canada/Mexico (64.3%), Europe and Australia (35,7%);

- generic prescription drugs (20%).

At the end of 2019, the group has 93 production sites worldwide.

Net sales break down geographically as follows: Ireland (0.5%), Europe (27.1%), the United States (66.7%) and other (5.7%).

Number of employees : 11 200 people.
Sales per Businesses
20182019Delta
USD (in Million)%USD (in Million)%
Consumer Self-Care Americas2,41251%2,48851.4% +3.16%
Consumer Self-Care International1,49631.6%1,38228.6% -7.6%
Prescription Pharmaceuticals824.2017.4%967.5020% +17.39%
Sales per Regions
20182019Delta
USD (in Million)%USD (in Million)%
United States3,09865.5%3,22666.7% +4.11%
Europe1,32227.9%1,31227.1% -0.72%
All Other Countries285.806%276.005.7% -3.43%
Ireland25.700.5%23.400.5% -8.95%
Managers
NameAgeSinceTitle
Murray Kessler582018President, Chief Executive Officer & Director
Rolf Classon732018Chairman
Raymond P. Silcock682019Chief Financial & Accounting Officer
Thomas Farrington612015Chief Information Officer & Executive VP
Grainne Quinn, Dr.492016Chief Medical Officer & Executive Vice President
James E. Dillard552019Chief Scientific Officer & Executive VP
Donal M. O'Connor672014Independent Director
Geoffrey M. Parker532016Independent Director
Theodore Rapp Samuels632017Independent Director
Bradley A. Alford612017Independent, Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 136,126,977 135,485,690 99.5% 0 0.0% 99.5%
Shareholders
NameEquities%
T. Rowe Price Associates, Inc. (Investment Management) 20,173,813 14.8%
The Vanguard Group, Inc. 15,556,333 11.4%
SSgA Funds Management, Inc. 6,286,612 4.62%
Franklin Mutual Advisers LLC 4,151,182 3.05%
Starboard Value LP 4,100,000 3.01%
Southeastern Asset Management, Inc. 4,038,200 2.97%
BlackRock Fund Advisors 3,520,400 2.59%
Carmignac Gestion SA 3,224,624 2.37%
Dimensional Fund Advisors LP 3,111,486 2.29%
Capital Research & Management Co. (Global Investors) 3,071,043 2.26%
Holdings
NameEquities%Valuation
Proteostasis Therapeutics, Inc. (PTI) 2,908,0675.69%4,536,585 USD
Markets and indexes
- NYSE
- Main Market
- SP 500 /
Stock Exchange Codes
- Bloomberg Code :  
- Reuters Code :  PRGO.N
- Datastream Code :  
Company contact information
Perrigo Company plc
The Sharp Building 515 Hogan Place
IE-D02 TY74 Dublin 2
Ireland

Phone : +353 1 7094000
Fax : +353
Internet : http://www.perrigo.com
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
PERRIGO COMPANY PLC-10.76%6 275
JOHNSON & JOHNSON-13.23%324 693
ROCHE HOLDING AG-5.29%264 026
MERCK & CO., INC-21.13%181 927
NOVARTIS-16.30%180 007
PFIZER, INC.-21.13%171 422
NOVO NORDISK A/S-0.69%133 274
ELI LILLY AND COMPANY2.04%121 643
BRISTOL-MYERS SQUIBB COMPANY-17.76%119 435
AMGEN INC.-17.75%116 941
ASTRAZENECA PLC-10.54%110 838
ABBVIE INC.-17.92%107 310
SANOFI-14.08%106 806
GLAXOSMITHKLINE-18.89%89 147
CHUGAI PHARMACEUTICAL CO., LTD.-7.80%58 774
ALLERGAN PLC-9.50%56 917
JIANGSU HENGRUI MEDICINE CO., LTD.3.15%56 410
BAYER AG-30.41%55 194
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.73%49 361
DAIICHI SANKYO COMPANY, LIMITED-4.17%45 583
ASTELLAS PHARMA INC.2.70%29 657